Always looking for good investments.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am with you on that one.. OCTI is looking very good. :)
LPTN .81 - check this out!!!!
LPTN: Lpath (LPTN.OB) already has the attention of a powerhouse pharmaceutical giant, and that relationship only fuels the speculation that Pfizer (PFE) might make the ultimate jump and buy out its small time partner now, while the company is still considered cheap.
Lpath has developed a technology, through its proprietary ImmuneY2 platform, that generates antibodies that target bioactive lipids and inhibit the growth and spreading of various diseases and inflammatory/auto-immune disorders.
Advancements in the field of bioactive lipids have been gaining traction in the medical community over recent years, and Lpath is the only company to take it as far as it has. That success is what undoubtedly brought Pfizer to the bargaining table and landed Lpath a very significant deal for a Phase II company from a global behemoth.
Pfizer is already partnered for Lpath's iSONEP, a potential treatment for retinal pigment epithelium detachment ("RPE detachment" or "PED") and Wet AMD, but the licensing agreement also grants Pfizer the first right of refusal for ASONEP, a potential treatment for various cancer types.
Big players don't jump on still-developing companies without having a great deal of confidence in the technology behind the pipeline, which is sure to fuel takeover speculation regarding Pfizer and Lpath.
http://seekingalpha.com/article/310501-10-buyout-candidates-to-watch
LPTN .81 - check this out!!!!
LPTN: Lpath (LPTN.OB) already has the attention of a powerhouse pharmaceutical giant, and that relationship only fuels the speculation that Pfizer (PFE) might make the ultimate jump and buy out its small time partner now, while the company is still considered cheap.
Lpath has developed a technology, through its proprietary ImmuneY2 platform, that generates antibodies that target bioactive lipids and inhibit the growth and spreading of various diseases and inflammatory/auto-immune disorders.
Advancements in the field of bioactive lipids have been gaining traction in the medical community over recent years, and Lpath is the only company to take it as far as it has. That success is what undoubtedly brought Pfizer to the bargaining table and landed Lpath a very significant deal for a Phase II company from a global behemoth.
Pfizer is already partnered for Lpath's iSONEP, a potential treatment for retinal pigment epithelium detachment ("RPE detachment" or "PED") and Wet AMD, but the licensing agreement also grants Pfizer the first right of refusal for ASONEP, a potential treatment for various cancer types.
Big players don't jump on still-developing companies without having a great deal of confidence in the technology behind the pipeline, which is sure to fuel takeover speculation regarding Pfizer and Lpath.
http://seekingalpha.com/article/310501-10-buyout-candidates-to-watch
Agree.. these share are cheap right now.. I'm adding as much as i can and wait for the buyout.
OCTI - Hold GAINS WELL.. Looking for more soon!
Agree.. i think peeps are holding LPTN long term and will let Pfizer show us the $$$$$$$. :)
A bit more info LPTN
Another company that may be in line to receive an offer before the approval process is complete is Lpath Inc. (LPTN). Considering the potential catalysts in play and a prime-time partnership with Pfizer (PFE), Lpath shares may be undervalued right now.
Lpath has become a recognized leader in the field of developing lipid-based therapies through its proprietary ImmuneY2 platform, which contains the ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to the spreading and growth of various diseases and inflammatory/auto-immune disorders. The market potential for this technology in treating a plethora of modern day illnesses and diseases, should it advance past the clinical stages, is huge. Lpath is first applying this technology to treat Wet AMD and cancer, both multi-billion dollar markets, and that could just be the beginning.
http://www.pharmanewswire.com/?prID=94425
LPTN - check this out!!!!
LPTN: Lpath (LPTN.OB) already has the attention of a powerhouse pharmaceutical giant, and that relationship only fuels the speculation that Pfizer (PFE) might make the ultimate jump and buy out its small time partner now, while the company is still considered cheap.
Lpath has developed a technology, through its proprietary ImmuneY2 platform, that generates antibodies that target bioactive lipids and inhibit the growth and spreading of various diseases and inflammatory/auto-immune disorders.
Advancements in the field of bioactive lipids have been gaining traction in the medical community over recent years, and Lpath is the only company to take it as far as it has. That success is what undoubtedly brought Pfizer to the bargaining table and landed Lpath a very significant deal for a Phase II company from a global behemoth.
Pfizer is already partnered for Lpath's iSONEP, a potential treatment for retinal pigment epithelium detachment ("RPE detachment" or "PED") and Wet AMD, but the licensing agreement also grants Pfizer the first right of refusal for ASONEP, a potential treatment for various cancer types.
Big players don't jump on still-developing companies without having a great deal of confidence in the technology behind the pipeline, which is sure to fuel takeover speculation regarding Pfizer and Lpath.
http://seekingalpha.com/article/310501-10-buyout-candidates-to-watch
LPTN - .80 UP ~~ Very thin here!
OCTI - .0145 HOD HITTING, only 5K left on the offer!!!!
OCTI - .0145 HOD HITTING, only 5K left on the offer!!!!
OCTI - .0145 nice steady moves upward.
Agree.. LPTN is another sleeper waiting for a spark to head upward in a hurry.
I see PUMA bidding shares on LPTN. That's a BIG BOY loading up.
Very nice call on IMDS ~Blue~.. It continues to impress!
Me too.. The OCTI chart looks very impressive today.
Indeed. LPTN has a very bright future. This is a keeper.
OCTI - .0145 hits ~~ Only 5K left showing..
OCTI - .0145 HOD Hits ~~ Another above AVG volume day..
OCTI - .0145 hits ~~ Another above AVG volume day..
OCTI - Another above AVG volume day. The PPS will FOLLOW soon!!!
OCTI - Another above AVG volume day..
Exactly.. Bigger drug companies have been on the move buying out other smaller companies. I can see LPTN as target.
OCTI - .0145 tapped.. Looking very Bullish today!!!
OCTI - .0145 tapped.. Looking very Bullish today!!!
Looking very good bullmarket2222.. chart is looking HOT for a BIG MOVE north! IM
OCTI - .0141 x .0145 UP NOW..
Very good DD there alexindef.
Thanks.. too good of an opportunity to pass up here.
I sure would take it.. I hope peeps have shares???
No doubt about that.. with Wal-Mart & Target as customers of OCTI lookout above!!!!
Took a starter on LPTN today.. Like my chances here for a buyout.
Agree. A Golden Cross is in the future for OCTI. :)
OCTI Chart link.
http://stockcharts.com/h-sc/ui?s=OCTI
LPTN * ANTH * OCTI - Very nice plays for Flextraders!
OCTI - Chart looking very bullish!
OCTI - Another block trade.. Chart very BULLISH!!!
OCTI ~.0141 - GOLDEN CROSS soon and nice bids checking in on this undervalued gem.
OCTI ~.0141 - GOLDEN CROSS soon and nice bids checking in on this undervalued gem.
OCTI - .141 Hitting, ONLY 18K left!!!!